Literature DB >> 32866728

Evaluation of the respiratory syncytial virus G-directed neutralizing antibody response in the human airway epithelial cell model.

Michael Kishko1, John Catalan1, Kurt Swanson2, Josh DiNapoli1, Chih-Jen Wei2, Simon Delagrave1, Sudha Chivukula1, Linong Zhang3.   

Abstract

Human respiratory syncytial virus (RSV) is a major cause of serious respiratory tract infections in infants and the elderly. Recently it was shown that the RSV G glycoprotein mediates attachment to cells using CX3CR1 as a receptor, and that G-specific neutralizing antibodies can be detected using human airway epithelial (HAE) cell cultures. To investigate the contributions of G-specific antibodies to RSV neutralization, we performed HAE neutralization assays on sera from RSV G-immunized mice or RSV-infected infants. We confirmed that G-specific neutralization using serum from mice or humans could only be detected on HAE cultures. We also found that RSV G-specific antibodies in infants were either subgroup specific or cross-neutralizing. Altogether, our results suggest that G is an important target for generating neutralizing antibodies and would be beneficial to include in an RSV vaccine. Further, inclusion of G antigens from both RSV subgroups may enhance the vaccine cross protection potency.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cross-neutralization; G; HAE; Neutralization; RSV; Subgroup

Mesh:

Substances:

Year:  2020        PMID: 32866728     DOI: 10.1016/j.virol.2020.08.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  3 in total

1.  Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle.

Authors:  Jennifer N Rainho-Tomko; Vincent Pavot; Michael Kishko; Kurt Swanson; Darin Edwards; Heesik Yoon; Lilibeth Lanza; Judith Alamares-Sapuay; Robert Osei-Bonsu; Sophia T Mundle; Dave A Murison; Scott Gallichan; Simon Delagrave; Chih-Jen Wei; Linong Zhang; Gary J Nabel
Journal:  NPJ Vaccines       Date:  2022-06-30       Impact factor: 9.399

2.  Viral RNA N6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus.

Authors:  Miaoge Xue; Yuexiu Zhang; Haitao Wang; Elizabeth L Kairis; Mijia Lu; Sadeem Ahmad; Zayed Attia; Olivia Harder; Zijie Zhang; Jiangbo Wei; Phylip Chen; Youling Gao; Mark E Peeples; Amit Sharma; Prosper Boyaka; Chuan He; Sun Hur; Stefan Niewiesk; Jianrong Li
Journal:  PLoS Pathog       Date:  2021-12-20       Impact factor: 6.823

3.  Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity.

Authors:  Clara Maier; Jana Fuchs; Pascal Irrgang; Michael Hermann Wißing; Jasmin Beyerlein; Matthias Tenbusch; Dennis Lapuente
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.